logo
Parents, midwives mourn closure of family birth unit at Montreal's Notre-Dame Hospital

Parents, midwives mourn closure of family birth unit at Montreal's Notre-Dame Hospital

CBC29-03-2025

It cost $25 million to build, but barely a year after its opening and less than six months in operation, the family birth unit at Montreal's Notre-Dame Hospital is closed for good.
The CIUSSS du Centre-Sud-de-l'Île-de-Montréal, which oversees the hospital, announced the closure a week ago, blaming a lack of specialized obstetrics staff.
The loss is a "missed opportunity" and a blow for patients who would prefer to give birth outside of a traditional hospital setting, said Barbara Beccafico, a birth doula and board member with the Quebec Association of Doulas (AQD).
"The community was very saddened," said Beccafico. "We felt like it was a beautiful project that was stillborn."
The family birth unit emphasized physiological — or natural — medication-free births and collaborated with midwives, who shared their expertise and knowledge with the unit's nurses.
The unit was supposed to accommodate 1,500 births a year or 125 a month. In the end, only 46 children were born there.
In an email, Amaili Jetté, the president of the Regroupement les sages-femmes du Québec (RSFQ), a collective representing midwife groups, said it's important these kinds of collaborations continue in the future, while respecting each other's areas of competence and expertise.
"Physiological births are in demand, and it is vital that we continue to offer care and facilities that meet the needs of the population," said Jetté, adding that the island of Montreal currently has five birthing centres and one midwifery service.
Bridge between home and hospital
Shannon Godin had planned on delivering her son, Tomas, at Notre-Dame Hospital, which is close to her home.
The Notre-Dame unit was designed as a bridge between the experience of home births and that of hospital deliveries.
Unlike a traditional hospital setting, the family birth unit had large, private rooms equipped with bath tubs. Birthing balls, stools and other supports such as slings and ceiling bars were also available to help patients during delivery.
The patient would remain in the same room to recover rather than changing units, which Godin also liked.
But when the family birth unit was temporarily closed last summer, Godin began to search for another option.
A nurse herself, she said she isn't surprised the unit struggled to maintain staffing due to the nursing shortage throughout the health- care system. Even so, she admits it was "frustrating and disappointing" to have to start over and find a new place to give birth.
"It's too bad that they went ahead and built it when they didn't have the resources to actually run it," said Godin.
Needs have evolved
The Notre-Dame Hospital family birth unit has faced a lot of challenges.
Construction delays, recruitment difficulties and the COVID-19 pandemic postponed the project several times.
It finally opened in February 2024.
But by the summer, the unit had to temporarily suspend operations due to staffing difficulties, reduced availability of obstetricians and the arrival of the summer holiday period, said Marianne Paquette, a spokesperson for CIUSSS du Centre-Sud-de-l'Île-de-Montréal.
Last fall, the unit postponed its reopening indefinitely and an external consultant from the Health Ministry was called in to try to find a solution.
Despite several recruitment drives, "specialized labour in this field is scarce and we have not been able to fill a sufficient number of positions to ensure a safe reopening," said Paquette.
Paquette said the community's needs have also evolved since the project started seven years ago.
The regional health authority said other birthing centres in greater Montreal have the capacity to handle the demand, given that latest projections show the birth rate will continue to decline.
When Health Minister Christian Dubé was asked about the short-lived unit, he used it as an example to underline the importance of Santé Québec, the new Crown corporation responsible for the province's health-care system.
"There were a lot of projects that were looked [at] on a standalone basis by an establishment," said Dubé. "We cannot just spend money on a local basis without thinking globally."
But Beccafico said that decision is shortsighted.
Although they understand the province is always looking to get the most bang for its buck, they say more and more people are interested in giving birth outside of a traditional hospital setting.
"By shutting down this initiative, they are sending a clear message: budget priorities matter more than parents' choices," said Beccafico.
They believe the real issue is a lack of commitment, support and training for this birthing option, which in the end, could help save money.
Beccafico believes a patient-centric approach that focuses on natural births can help patients feel empowered and may even help lower the chances of postpartum depression.
The CIUSSS du Centre-Sud-de-l'Île-de-Montréal has met with all the employees and doctors about the closure.
Many of the unit's nurses and orderlies were already re-distributed to other birthing centres after Notre-Dame's unit closed last summer.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI Tool 'KIBIT': A Game Changer in New Drug Development
AI Tool 'KIBIT': A Game Changer in New Drug Development

Japan Forward

timean hour ago

  • Japan Forward

AI Tool 'KIBIT': A Game Changer in New Drug Development

このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む

Neurenati Announces its First Scientific and Clinical Advisory Board Meeting with KOLs to Advance the Development of NEU-001, a Promising Cure for Hirschsprung Disease
Neurenati Announces its First Scientific and Clinical Advisory Board Meeting with KOLs to Advance the Development of NEU-001, a Promising Cure for Hirschsprung Disease

National Post

time20 hours ago

  • National Post

Neurenati Announces its First Scientific and Clinical Advisory Board Meeting with KOLs to Advance the Development of NEU-001, a Promising Cure for Hirschsprung Disease

Article content MONTRÉAL — Neurenati, an innovative biotechnology company dedicated to developing cutting-edge therapies for unmet medical needs in rare pediatric diseases, is excited to announce the successful convening of its inaugural Scientific and Clinical Advisory Board (SCAB) meeting. This pivotal meeting recently brought together leading pediatric surgeons, gastroenterologists, and industry experts in regulatory affairs and drug development to collaboratively shape a strategic roadmap for advancing NEU-001, a fixed combination of glial cell derived growth factor (GDNF) and butyrate, into clinical stage. Article content The SCAB of Neurenati is composed of Dr Jacob Langer (pediatric surgeon, previously at SickKids Hospital, Toronto), Dr Tomas Wester (pediatric surgeon, Karolinska University Hospital, Stockholm), Dr Anne Dariel (pediatric surgeon, La Timone Hospital, Marseille), Dr Kattayoun Kordy (pediatric gastroenterologist, Founder and CEO Lucien Bio), and Dr Andrew Mulberg (pediatric gastroenterologist and former division deputy director of gastroenterology and inborn errors products, Center for Drug Evaluation and Research, US FDA). Article content The meeting served as a valuable platform for transatlantic dialogue, to share insights on the preclinical prospects of direct benefit, clinical trial design, and regulatory pathways for NEU-001. The diversity of expertise provided Neurenati with meaningful guidance on best clinical practices in both North America and Europe, a deeper understanding of the patient journey, and—most importantly—confirmed the urgent need to advance therapeutic solutions for individuals affected by Hirschsprung disease. 'Hirschsprung disease is an uncommon condition that affects approximately one in 5,000 children. The only effective treatment at this time is a major surgical operation. The innovative work being done by Neurenati could revolutionize the treatment of this disease and could potentially avoid the need for surgery in these tiny children,' said Dr Langer. 'Novel non-operative treatment options for Hirschsprung disease would have a significant impact on future management of these neonates,' confirmed Dr Wester. Article content Looking ahead, Neurenati is committed to leverage a strong collaboration with its scientific and clinical advisory board members as it navigates the path towards IND filing, ensuring that NEU-001 meets the highest standards of safety and efficacy. 'We are thrilled to have gathered such an esteemed group of thought leaders who are passionate about advancing the field of medicine,' said Meriam Kabbaj, DPharm, PhD, Chief Development Officer of Neurenati. 'Their contributions will be instrumental in shaping Neurenati's approach as it prepares for the next phase of its clinical program, with a strong focus on delivering a safe and effective therapy to pediatric patients in need.' Article content Article content Article content Article content Article content Contacts Article content Media Contact:

RFK Jr. removes all 17 members of U.S. vaccine advisory panel
RFK Jr. removes all 17 members of U.S. vaccine advisory panel

Global News

timea day ago

  • Global News

RFK Jr. removes all 17 members of U.S. vaccine advisory panel

U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the Biden administration had installed the entire committee. 'Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028,' Kennedy wrote in a Wall Street Journal opinion piece. 'A clean sweep is needed to re-establish public confidence in vaccine science.' Story continues below advertisement Kennedy said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster 'a coup.' 'It's not how democracies work. It's not good for the health of the nation,' Benjamin told The Associated Press. 0:37 RFK announces COVID vaccine removal from immunization schedule for pregnant women and children Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy 'like a hawk.' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'He is breaking a promise,' Benjamin said. 'He said he wasn't going to do this.' Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases. Story continues below advertisement 'Today's action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives,' Scott said in a statement. Republican Sen. Bill Cassidy of Louisiana, a doctor who had expressed reservations about Kennedy's nomination but voted to install him as the nation's health secretary nonetheless, said he had spoken with Kennedy moments after the announcement. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy said in a social media post. 'I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' 9:34 RFK Jr. and Elizabeth Warren get into heated debate over vaccine question at confirmation hearing The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Story continues below advertisement During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations. Kennedy did not stick to that. He recently took the unusual step of changing COVID-19 recommendations without first consulting the advisers. The webpage that featured the committee's members was deleted Monday evening, shortly after Kennedy's announcement.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store